Including Imfinzi to chemotherapy earlier than and after surgical procedure improved survival and response charges in resectable gastric and gastroesophageal junction most cancers.
Including Imfinzi (durvalumab) to FLOT (fluorouracil, leucovorin, oxaliplatin and docetaxel) chemotherapy earlier than and after surgical procedure improved event-free survival in comparison with placebo plus FLOT for sufferers with resectable gastric or or gastroesophageal junction (GEJ) adenocarcinoma, in accordance with knowledge from the part 3 MATTERHORN trial.
Findings introduced in a press briefing on the 2025 ASCO Annual Assembly confirmed that at a median follow-up of 31.6 months for the Imfinzi arm (474 sufferers) and 31.4 months for the placebo arm (474 sufferers), Imfinzi plus FLOT generated a median EFS that was not reached in contrast with 32.8 months for placebo plus FLOT. Within the Imfinzi arm, the 18- and 24-month EFS charges have been 73% and 67%, respectively. These respective charges have been 64% and 59% within the placebo arm.
“The [EFS] profit was seen throughout prespecified [subgroup] cohorts. We didn’t see any new security indicators. [Therefore], this may change apply for our sufferers, which is thrilling to see,” lead examine writer Dr. Yelena Y. Janjigian, mentioned within the press briefing.
Janjigian is chief of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Most cancers Middle in New York, New York.
Security of the Trial
Relating to security, any-grade antagonistic results (AEs; negative effects) occurred in 99% of sufferers in each arms. The charges of AEs probably associated to review remedy have been each 95%. The charges of grade 3/4 AEs have been 72% for the Imfinzi arm versus 71% for the placebo arm. Grade 3 (extreme)/4 (life-threatening) AEs probably associated to remedy occurred at charges of 60% and 59%, respectively. The charges of great AEs have been 48% for the Imfinzi arm versus 44% for the placebo arm.
AEs led to remedy discontinuation of any examine remedy in 30% of sufferers within the experimental arm versus 23% of sufferers within the management arm. Ten p.c of sufferers discontinued Imfinzi resulting from AEs, whereas 6% discontinued placebo. FLOT was discontinued resulting from AEs in 25% and 20% of sufferers, respectively.
AEs led to demise in 5% of sufferers within the Imfinzi arm versus 4% of sufferers within the placebo arm. These AEs have been deemed probably associated to Imfinzi or placebo in 1% and fewer than 1% of sufferers, respectively. AEs resulting in demise that have been probably associated to FLOT occurred at respective charges of 1% and fewer than 1%.
Any-grade immune-mediated AEs (irAEs) have been reported in 23% of sufferers within the Imfinzi group versus 7% of sufferers within the placebo arm. The charges of grade 3/4 irAEs have been 7% and 4%, respectively.
Surgical procedure was not carried out resulting from AEs in 1% of sufferers within the experimental arm versus lower than 1% of sufferers within the management arm. The charges of AEs resulting in a delay in surgical procedure have been 2% and three%, respectively.
Scaling the MATTERHORN
Investigators of the worldwide, double-blind, placebo-controlled trial enrolled sufferers with stage 2 to 4a gastric/GEJ adenocarcinoma who had no proof of metastases and acquired no prior remedy. Sufferers additionally wanted to have an ECOG efficiency standing of 0 or 1.
Sufferers have been randomly assigned 1:1 to the Imfinzi or placebo arm. Neoadjuvant remedy lasted two cycles, comprising Imfinzi at 1500 milligrams (mg) as soon as each 4 weeks plus FLOT or placebo plus FLOT. Following surgical procedure, sufferers acquired 2 extra cycles of Imfinzi at 1500 mg as soon as each 4 weeks plus FLOT, or placebo plus FLOT. Sufferers then acquired Imfinzi at 1500 mg as soon as each 4 weeks or placebo as monotherapy for 10 extra adjuvant cycles.
Key stratification elements included area (Asia versus non-Asia), medical stage (N+ versus N–), and PD-L1 standing (tumor space positivity [TAP] lower than 1% versus TAP greater than or equal to 1%).
EFS served because the trial’s main finish level. General survival (OS), pathological full response (pCR) charge, and disease-free survival (DFS) have been key secondary finish factors.
All sufferers within the Imfinzi arm acquired any neoadjuvant remedy in contrast with 99% of sufferers within the placebo arm. Neoadjuvant remedy with Imfinzi or placebo was accomplished in 97% and 95% of sufferers, respectively. The respective charges of sufferers who accomplished neoadjuvant FLOT have been 96% and 95%.
Surgical procedure was tried in 91% of sufferers within the Imfinzi arm versus 90% of these within the placebo arm. Surgical procedure was accomplished in 87% and 84% of sufferers, respectively. The charges of R0 resection have been 92% in each arms. Any adjuvant remedy was given to 77% of sufferers within the Imfinzi group versus 74% of sufferers within the placebo group. Fifty-two p.c of sufferers in each arms accomplished adjuvant Imfinzi or placebo; 61% and 64%, respectively, accomplished adjuvant FLOT. On the knowledge cutoff, 68% of sufferers within the Imfinzi arm and 59% of sufferers within the placebo arm have been actively in follow-up.
At baseline, the median age was 62 years within the Imfinzi arm versus 63 years within the placebo arm. The vast majority of sufferers in each teams have been male (Imfinzi, 69%; placebo, 75%), from areas outdoors of Asia (81%; 81%), had an ECOG efficiency standing of 0 (71%; 77%), had gastric tumors (68%; 67%), had non-T4 illness (75%; 75%), had node-positive illness (69%; 70%), had a PD-L1 TAP of at the very least 1% (90%; 90%), had an intestinal histology (52%; 50%), and didn’t have microsatellite instability–excessive illness (64%; 65%).
Secondary Finish Factors
The median OS was NR within the Imfinzi arm versus 47.2 months within the placebo arm. The 18- and 24-month OS charges have been 81% and 76%, respectively, within the Imfinzi arm. These respective charges have been 77% and 70% within the placebo arm. The median follow-up for OS was 34.6 months within the Imfinzi group versus 34.6 months within the placebo group.
Sufferers within the Imfinzi arm achieved a pCR charge of 19% in contrast with 7% for these within the placebo arm, translating to a 12% distinction.
The median DFS was NR within the Imfinzi arm versus 39.8 months within the placebo arm. The 18- and 24-month DFS charges have been 79% and 75%, respectively, for Imfinzi plus FLOT versus 73% and 66%, respectively, for placebo plus FLOT.
Sufferers in each arms acquired a median of two neoadjuvant cycles of Imfinzi/placebo and FLOT. They acquired a median of 12 adjuvant cycles of Imfinzi/placebo and a median of two adjuvant cycles of FLOT. All sufferers acquired at the very least one neoadjuvant cycle of Imfinzi/placebo plus FLOT. Precisely two cycles of neoadjuvant Imfinzi and FLOT have been every given to 97% of sufferers within the experimental arm; these charges have been each 96% within the management arm.
Within the experimental arm, at the very least one cycle of adjuvant Imfinzi and FLOT was given to 76% and 75% of sufferers, respectively. The charges of sufferers who acquired at the very least two cycles of every have been 73% and 67%, respectively. Seventy-two p.c of sufferers acquired at the very least three cycles of adjuvant Imfinzi, and 52% acquired 12 cycles. Within the management arm, at the very least one cycle of adjuvant placebo and FLOT was given to 74% of sufferers every. Seventy-two p.c acquired at the very least two placebo cycles, and 68% accomplished two adjuvant FLOT cycles. Seventy-one p.c of sufferers accomplished at the very least three cycles of adjuvant placebo, and 51% accomplished the total 12-cycle adjuvant placebo course.
Reference:
“Occasion-free survival in MATTERHORN” by Dr. Yelena Janjigian, et al., Journal of Medical Oncology
For extra information on most cancers updates, analysis and training, don’t overlook to subscribe to CURE®’s newsletters right here.
